adalimumab, da der ikke findes passende modeller for et antistof med begrænset krydsreaktivitet over for gnaver- TNF og udviklingen af neutraliserende antistoffer hos gnavere. mi
tho fertility and postnatal toxicity, were not performed with adalimumab due to the lack of appropriate models for an antibody with limited cross-reactivity to rodent TNF and the development of neutralizing antibodies in rodents.